Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.2% – Here’s Why

Shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) traded down 5.2% during mid-day trading on Wednesday . The company traded as low as $8.20 and last traded at $8.53. 19,089 shares traded hands during mid-day trading, an increase of 47% from the average session volume of 13,015 shares. The stock had previously closed at $9.00.

Nanobiotix Trading Down 5.2%

The business’s fifty day simple moving average is $5.93 and its 200 day simple moving average is $4.43.

Hedge Funds Weigh In On Nanobiotix

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC acquired a new position in shares of Nanobiotix during the 4th quarter worth about $29,000. Millennium Management LLC bought a new position in Nanobiotix during the 4th quarter worth approximately $39,000. Finally, Jane Street Group LLC acquired a new position in Nanobiotix during the fourth quarter valued at approximately $73,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.